XML 17 R5.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders’ Deficit - USD ($)
Common Stock
Additional Paid-in capital
Accumulated other comprehensive loss
Accumulated deficit
Series A convertible preferred stock
Series B convertible preferred stock
Series C convertible preferred stock
Total
Temporary equity, beginning balance at Dec. 31, 2018         $ 6,483,044 $ 49,742,942 $ 56,364,645  
Temporary Equity, Beginning Balance (in shares) at Dec. 31, 2018         612,446 7,235,969 4,712,698  
Increase (Decrease) in Temporary Equity                
Issuance of convertible preferred stock, net of issuance costs             $ 5,598,362  
Issuance of convertible preferred stock (in shares)             467,179  
Temporary equity, ending balance at Jun. 30, 2019         $ 6,483,044 $ 49,742,942 $ 61,963,007  
Temporary Equity, Ending Balance (in shares) at Jun. 30, 2019         612,446 7,235,969 5,179,877  
Equity, beginning balance at Dec. 31, 2018 $ 127,091 $ 19,666,588 $ (8,761,325) $ (62,468,456)       $ (51,436,102)
Equity, beginning balance (in shares) at Dec. 31, 2018 1,155,366              
Increase (Decrease) in Stockholders' Equity                
Exercise of stock options $ 2,883 20,235           23,118
Exercise of stock options (in shares) 26,207              
Stock‑based compensation   284,909           284,909
Foreign currency translation     (1,986,667)         (1,986,667)
Net loss       (8,737,650)       (8,737,650)
Equity, ending balance at Jun. 30, 2019 $ 129,974 19,971,732 (10,747,992) (71,206,106)       (61,852,392)
Equity, ending balance (in shares) at Jun. 30, 2019 1,181,573              
Temporary equity, beginning balance at Dec. 31, 2018         $ 6,483,044 $ 49,742,942 $ 56,364,645  
Temporary Equity, Beginning Balance (in shares) at Dec. 31, 2018         612,446 7,235,969 4,712,698  
Equity, beginning balance at Dec. 31, 2018 $ 127,091 19,666,588 (8,761,325) (62,468,456)       (51,436,102)
Equity, beginning balance (in shares) at Dec. 31, 2018 1,155,366              
Increase (Decrease) in Stockholders' Equity                
Foreign currency translation               (4,926,841)
Net loss               (14,987,069)
Equity, ending balance at Sep. 30, 2019 $ 1,182 20,346,849 (13,688,166) (77,455,525) $ 6,483,044 $ 49,742,942 $ 61,963,007 (70,795,660)
Equity, ending balance (in shares) at Sep. 30, 2019 1,181,733       612,446 7,235,969 5,179,877  
Temporary equity, beginning balance at Jun. 30, 2019         $ 6,483,044 $ 49,742,942 $ 61,963,007  
Temporary Equity, Beginning Balance (in shares) at Jun. 30, 2019         612,446 7,235,969 5,179,877  
Equity, beginning balance at Jun. 30, 2019 $ 129,974 19,971,732 (10,747,992) (71,206,106)       (61,852,392)
Equity, beginning balance (in shares) at Jun. 30, 2019 1,181,573              
Increase (Decrease) in Stockholders' Equity                
Issuance of common stock $ 100             100
Issuance of common stock (in shares) 160              
Stock‑based compensation   246,225           246,225
Foreign currency translation     (2,940,174)         (2,940,174)
Exchange of preferred and common stock of Aprea Therapeutics AB into stock of Aprea Therapeutics, Inc. $ (128,892) 128,892            
Net loss       (6,249,419)       (6,249,419)
Equity, ending balance at Sep. 30, 2019 $ 1,182 20,346,849 (13,688,166) (77,455,525) $ 6,483,044 $ 49,742,942 $ 61,963,007 (70,795,660)
Equity, ending balance (in shares) at Sep. 30, 2019 1,181,733       612,446 7,235,969 5,179,877  
Equity, beginning balance at Dec. 31, 2019 $ 21,023 226,284,548 (11,533,778) (90,528,263)       124,243,530
Equity, beginning balance (in shares) at Dec. 31, 2019 21,022,752              
Increase (Decrease) in Stockholders' Equity                
Exercise of stock options $ 164 150,785           150,949
Exercise of stock options (in shares) 164,075              
Stock‑based compensation   2,161,931           2,161,931
Foreign currency translation     (667,870)         (667,870)
Net loss       (25,768,184)       (25,768,184)
Equity, ending balance at Jun. 30, 2020 $ 21,187 228,597,264 (12,201,648) (116,296,447)       100,120,356
Equity, ending balance (in shares) at Jun. 30, 2020 21,186,827              
Equity, beginning balance at Dec. 31, 2019 $ 21,023 226,284,548 (11,533,778) (90,528,263)       124,243,530
Equity, beginning balance (in shares) at Dec. 31, 2019 21,022,752              
Increase (Decrease) in Stockholders' Equity                
Foreign currency translation               (836,852)
Net loss               (38,086,266)
Equity, ending balance at Sep. 30, 2020 $ 21,187 229,986,911 (12,370,630) (128,614,529)       89,022,939
Equity, ending balance (in shares) at Sep. 30, 2020 21,186,827              
Equity, beginning balance at Jun. 30, 2020 $ 21,187 228,597,264 (12,201,648) (116,296,447)       100,120,356
Equity, beginning balance (in shares) at Jun. 30, 2020 21,186,827              
Increase (Decrease) in Stockholders' Equity                
Stock‑based compensation   1,389,647           1,389,647
Foreign currency translation     (168,982)         (168,982)
Net loss       (12,318,082)       (12,318,082)
Equity, ending balance at Sep. 30, 2020 $ 21,187 $ 229,986,911 $ (12,370,630) $ (128,614,529)       $ 89,022,939
Equity, ending balance (in shares) at Sep. 30, 2020 21,186,827